阿兹夫定在进展为危重症风险升高的有症状成人COVID-19参与者中的疗效与安全性:一项多中心随机双盲安慰剂对照III期试验的研究方案
本研究为多中心、随机、双盲、安慰剂对照III期临床试验,计划纳入1096例有轻至中度症状且有进展为重症COVID-19高风险的成人患者。患者随机接受阿兹夫定片5 mg每日一次最长7天或安慰剂每日五片,主要结局为28天内COVID-19相关危重症及全因死亡率。
要点
- 阿兹夫定是一种核苷类似物,低成本且药物相互作用少,但高质量临床验证仍有限。
- 试验纳入1096例有轻至中度症状且进展为重症COVID-19高风险的成人患者。
- 主要结局为28天内两组COVID-19相关危重症及全因死亡的比例。
核心结论
- 本试验旨在确定阿兹夫定能否防止有重症风险的患者进展为危重症和死亡,结果将判断阿兹夫定是否为COVID-19有效且可负担的抗病毒治疗选择。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照III期临床试验,纳入1096例有轻至中度症状且有进展为重症COVID-19高风险的成人患者。
- 患者随机接受阿兹夫定片5 mg每日一次最长7天或安慰剂每日五片。
- 所有参与者除研究药物外的抗病毒治疗外,允许使用标准治疗策略。
主要发现
- 主要结局为28天内两组COVID-19相关危重症及全因死亡的比例。
- 近期研究显示抗病毒治疗是防止患者进展为重症甚至死亡的关键因素。
- 阿兹夫定是一种核苷类似物,是潜在的低成本候选药物,药物相互作用少。
关键数值与推荐
- 阿兹夫定片5 mg每日一次,最长7天。
- 安慰剂每日五片。
- 主要结局:28天内COVID-19相关危重症及全因死亡的比例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 will coexist with humans for a long time, and it is therefore important to develop effective treatments for coronavirus disease 2019 (COVID-19). Recent studies have demonstrated that antiviral therapy is a key factor in preventing patients from progressing to severe disease, even death. Effective and affordable antiviral medications are essential for disease treatment and are urgently needed. Azvudine, a nucleoside analogue, is a potential low-cost candidate with few drug interactions. However, validation of high-quality clinical studies is still limited. METHODS: This is a multicentre, randomized, double-blind, placebo-controlled phase III clinical trial involving 1096 adult patients with mild-to-moderate symptoms of COVID-19 who are at high risk for progression to severe COVID-19. Patients will be randomized to (1) receive azvudine tablets 5 mg daily for a maximum of 7 days or (2) receive placebo five tablets daily. All participants will be permitted to use a standard treatment strategy except antiviral therapy beyond the investigational medications. The primary outcome will be the ratio of COVID-19-related critical illness and all-cause mortality among the two groups within 28 days. DISCUSSION: The purpose of this clinical trial is to determine whether azvudine can prevent patients at risk of severe disease from progressing to critical illness and death, and the results will identify whether azvudine is an effective and affordable antiviral treatment option for COVID-19. TRIAL REGISTRATION: ClinicalTrials.gov NCT05689034. Registered on 18 January 2023.
引用
- Tian X, Xu Y, Wang L, et al. Efficacy and safety of azvudine in symptomatic adult COVID-19 participants who are at increased risk of progressing to critical illness: a study protocol for a multicentre randomized double-blind placebo-controlled phase III trial. Trials. 2024. PMID: 38254211. doi:10.1186/s13063-024-07914-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。